Militia Capital Management LLC Acquires New Position in Medpace Holdings, Inc. $MEDP

Militia Capital Management LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 7,058 shares of the company’s stock, valued at approximately $3,389,000.

Several other large investors have also recently added to or reduced their stakes in the stock. NewEdge Advisors LLC boosted its position in Medpace by 22.1% during the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after purchasing an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in Medpace in the 2nd quarter worth about $296,000. Finally, M&T Bank Corp raised its stake in shares of Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on MEDP shares. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Mizuho lifted their target price on shares of Medpace from $495.00 to $586.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Royal Bank Of Canada reduced their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Barclays decreased their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research report on Friday, April 24th. Finally, Robert W. Baird restated a “neutral” rating and set a $547.00 price target (up from $477.00) on shares of Medpace in a research note on Wednesday, July 8th. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Medpace has a consensus rating of “Hold” and an average target price of $473.09.

Insider Transactions at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 20.50% of the stock is owned by company insiders.

Medpace Stock Performance

MEDP opened at $528.12 on Thursday. The company has a market cap of $15.08 billion, a PE ratio of 33.19, a price-to-earnings-growth ratio of 2.66 and a beta of 1.15. The stock has a 50-day moving average of $484.63 and a 200-day moving average of $493.49. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.53 million. During the same quarter last year, the company posted $3.10 earnings per share. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.